Brief: Eton Pharmaceuticals Says FDA Review Expected To Take 10 Months, Potential Q1 2026 Launch
28/04/2025 12:08
April 28 (Reuters) - Eton Pharmaceuticals Inc ETON.O: ETON PHARMACEUTICALS ANNOUNCES SUBMISSION OF NDA FOR ET-600 (DESMOPRESSIN ORAL SOLUTION) ETON PHARMACEUTICALS INC - FDA REVIEW EXPECTED TO TAKE 10 MONTHS, POTENTIAL Q1 2026 LAUNCH Source text: ID:nGNX33Gwcf Further company coverage: ETON.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eton Pharmaceuticals
See all newsBrief: Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing
Aquestive rises on US licensing deal for seizure drug with Eton Pharma
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer